drugset / Trial / NCT04812548
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
NaSequentialOpen-labelTreatment
Summary
The purpose of the study was to find out if the new drug sabatolimab when given in combination with azacitidine and venetoclax, was safe and had beneficial effects in participants with high or very high risk myelodysplastic syndrome (MDS) who were not suitable for treatment with intensive chemotherapy or a stem-cell transplant (HSCT).
Timeline
- Start
- 2021-05-31
- Primary completion
- 2023-05-08
- Completion
- 2023-05-08
Outcome
Outcome not reported
Stopped (Business): “Study was stopped following a strategic decision from the Sponsor. It was not based on any safety findings or safety concerns with sabatolimab.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sabatolimab | Monoclonal antibody | — | Intravenous |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |
| Background | Venetoclax | Small molecule | 400 mg | Oral |